Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1384

1.

KEYNOTE-025: Phase 1b Study of Pembrolizumab in Japanese Patients With Previously Treated PD-L1-Positive Advanced NSCLC.

Nishio M, Takahashi T, Yoshioka H, Nakagawa K, Fukuhara T, Yamada K, Ichiki M, Tanaka H, Seto T, Sakai H, Kasahara K, Satouchi M, Han SR, Noguchi K, Shimamoto T, Kato T.

Cancer Sci. 2019 Jan 7. doi: 10.1111/cas.13932. [Epub ahead of print]

2.

Phase II Study of Weekly Amrubicin for Refractory or Relapsed Non-small Cell Lung Cancer.

Kitagawa C, Iwasaku M, Kogure Y, Ando M, Yoshioka H, Nishiyama A, Watanabe N, Kunimasa K, Tsubouchi K, Oka S, Saka H.

In Vivo. 2019 Jan-Feb;33(1):163-166. doi: 10.21873/invivo.11453.

PMID:
30587617
3.

New scoring system in assessment of Hoffa's fat pad synovitis: A comparative study with established scoring systems.

Hagiwara S, Yang A, Takao S, Kaneko Y, Nozaki T, Yoshioka H.

World J Radiol. 2018 Nov 28;10(11):162-171. doi: 10.4329/wjr.v10.i11.162.

4.

The delivery of mRNA to colon inflammatory lesions by lipid-nano-particles containing environmentally-sensitive lipid-like materials with oleic acid scaffolds.

Tanaka H, Watanabe A, Konishi M, Nakai Y, Yoshioka H, Ohkawara T, Takeda H, Harashima H, Akita H.

Heliyon. 2018 Dec 3;4(12):e00959. doi: 10.1016/j.heliyon.2018.e00959. eCollection 2018 Dec.

5.

Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.

Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T.

J Thorac Oncol. 2018 Nov 20. pii: S1556-0864(18)33418-X. doi: 10.1016/j.jtho.2018.10.167. [Epub ahead of print]

PMID:
30468872
6.

Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer.

Yoshioka H, Kogure Y, Ando M, Kitagawa C, Iwasaku M, Niwa T, Saka H.

In Vivo. 2018 Nov-Dec;32(6):1581-1586. doi: 10.21873/invivo.11417.

PMID:
30348719
7.

Neuroprotective effects of microglial P2Y1 receptors against ischemic neuronal injury.

Fukumoto Y, Tanaka KF, Parajuli B, Shibata K, Yoshioka H, Kanemaru K, Gachet C, Ikenaka K, Koizumi S, Kinouchi H.

J Cereb Blood Flow Metab. 2018 Oct 18:271678X18805317. doi: 10.1177/0271678X18805317. [Epub ahead of print]

PMID:
30334687
8.

1O, 20O-diacetyl kamebakaurin protects against acetaminophen-induced hepatotoxicity in mice.

Yoshioka H, Nonogaki T, Ohnishi H, Fukuishi N, Yoshikawa M, Gui MY, Jin YR, Li XW, Adachi Y, Ohno N, Takeya K, Hitotsuyanagi Y, Miura N, Aoyagi Y.

Biomed Res. 2018;39(5):251-260. doi: 10.2220/biomedres.39.251.

9.

Excessive hair growth in a patient with psoriatic erythroderma following secukinumab administration.

Mashima E, Sawada Y, Yamaguchi T, Yoshioka H, Ohmori S, Haruyama S, Okada E, Nakamura M.

Eur J Dermatol. 2018 Aug 1;28(4):539-540. doi: 10.1684/ejd.2018.3327. No abstract available.

PMID:
30325327
10.

Stochastic differential game for management of non-renewable fishery resource under model ambiguity.

Yoshioka H, Yaegashi Y.

J Biol Dyn. 2018 Dec;12(1):817-845. doi: 10.1080/17513758.2018.1528394.

PMID:
30325271
11.

Sasa veitchii extract protects against carbon tetrachloride-induced hepatic fibrosis in mice.

Yoshioka H, Nonogaki T, Fukaya S, Ichimaru Y, Nagatsu A, Yoshikawa M, Fujii H, Nakao M.

Environ Health Prev Med. 2018 Oct 15;23(1):49. doi: 10.1186/s12199-018-0739-7.

12.

Embolization of a peripheral cerebral aneurysm associated with intracranial major artery occlusion through a transdural anastomotic artery: Case report.

Fukuda N, Kanemaru K, Hashimoto K, Yoshioka H, Senbokuya N, Yagi T, Kinouchi H.

Interv Neuroradiol. 2018 Sep 19:1591019918801539. doi: 10.1177/1591019918801539. [Epub ahead of print]

PMID:
30231796
13.

Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab.

Saito R, Sawada Y, Saito-Sasaki N, Yamamoto K, Yoshioka H, Ohmori S, Yoshioka M, Okada E, Nakamura M.

J Dermatol. 2018 Dec;45(12):1452-1455. doi: 10.1111/1346-8138.14643. Epub 2018 Sep 11.

PMID:
30204257
14.

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer.

Niki M, Nakaya A, Kurata T, Yoshioka H, Kaneda T, Kibata K, Ogata M, Nomura S.

Oncotarget. 2018 Aug 17;9(64):32298-32304. doi: 10.18632/oncotarget.25949. eCollection 2018 Aug 17.

15.

DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy.

Kawai M, Nakamura T, Miura N, Maeta M, Tanaka H, Ueda K, Higashi K, Moribe K, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

Nanomedicine. 2018 Nov;14(8):2587-2597. doi: 10.1016/j.nano.2018.08.006. Epub 2018 Aug 29.

PMID:
30170077
16.

Surgical outcomes and complications of pneumonectomy after induction therapy for non-small cell lung cancer.

Kayawake H, Okumura N, Yamanashi K, Otsuki Y, Takahashi A, Itasaka S, Yoshioka H, Nakashima T, Matsuoka T.

Gen Thorac Cardiovasc Surg. 2018 Nov;66(11):658-663. doi: 10.1007/s11748-018-0980-4. Epub 2018 Aug 6.

PMID:
30083866
17.

Microbial community structure in deep natural gas-bearing aquifers subjected to sulfate-containing fluid injection.

Katayama T, Yoshioka H, Yamanaka T, Takeuchi M, Muramoto Y, Usami J, Ikeda H, Sakata S.

J Biosci Bioeng. 2019 Jan;127(1):45-51. doi: 10.1016/j.jbiosc.2018.06.013. Epub 2018 Aug 3.

PMID:
30082219
18.

Development of an Alcohol Dilution-Lyophilization Method for Preparing Lipid Nanoparticles Containing Encapsulated siRNA.

Shirane D, Tanaka H, Nakai Y, Yoshioka H, Akita H.

Biol Pharm Bull. 2018;41(8):1291-1294. doi: 10.1248/bpb.b18-00208.

19.

Expression levels of brown/beige adipocyte-related genes in fat depots of vitamin A-restricted fattening cattle.

Chen HJ, Ihara T, Yoshioka H, Itoyama E, Kitamura S, Nagase H, Murakami H, Hoshino Y, Murakami M, Tomonaga S, Matsui T, Funaba M.

J Anim Sci. 2018 Jun 15. doi: 10.1093/jas/sky240. [Epub ahead of print]

PMID:
29912360
20.

Potentiating effect of acetaminophen and carbon tetrachloride-induced hepatotoxicity is mediated by activation of receptor interaction protein in mice.

Yoshioka H, Ichimaru Y, Fukaya S, Nagatsu A, Nonogaki T.

Toxicol Mech Methods. 2018 Oct;28(8):615-621. doi: 10.1080/15376516.2018.1485804. Epub 2018 Aug 2.

PMID:
29873576

Supplemental Content

Loading ...
Support Center